Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes

Endocrine

Volumn 32, Issue 3, 2007, Pages 311-316

  Chokrungvaranon, Nalurporn ^a   Chentanez, Teera ^a   Arakaki, Richard F ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

Asian and Pacific Islander patients; Clinical Experience; Exenatide

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; INSULIN; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; APPETITE; ARTICLE; ASIAN; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INJECTION SITE RASH; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PACIFIC ISLANDER; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; TREATMENT RESPONSE; VOMITING; WEIGHT;

EID: 46149094865     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-008-9042-5     Document Type: Article

References (15)

1. K. Dungan, J.B. Buse, Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exenatide. Clin. Diabetes 23, 56-62 (2005)
2. M.-B. Toft-Nielsen, M.B. Damholt, S. Madsbad, L.M. Hilsted, T.E. Hughes, B.K. Michelsen, J.J. Holst, Determinants of the impaired secretion of glucagons-like peptide-1 in type 2 diabetic patients. J. Clin. Endocrinol. 86(8), 3717-3723 (2001)
3. M.-B. Toft-Nielsen, S. Madsbad, J.J. Holst, Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J. Clin. Endocrinol. 86(8), 3853-3860 (2001)
4. D.J. Drucker, M.A. Nauck, The incretin system: glucacon-like peptide-1 receptor agonists and dipeptyl peptidase-4 inhibitors in type 2 diabetes Lancet 368(9548), 1696-1705 (2006)
5. J. Schirra, B. Goke, The physiological role of GLP-1 in human: incretin, ileal brake or more? Regul. Pept. 128, 109-115 (2005)
6. R.A. DeFronzo, R.E. Ratner, J. Han, D.D. Kim, M.S. Fineman, A.D. Baron, Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28(5), 1092-1100 (2005)
7. D.M. Kendall, M.C. Riddle, J. Rosenstock, D. Zhuang, D.D. Kim, M.S. Fineman, A.D. Baron, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28(5), 1083-1091 (2005)
8. J.B. Buse, R.R. Henry, J. Han, D.D. Kim, M.S. Fineman, A.D. Baron, Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27(11), 2628-2635 (2004)
9. J.A. Loh, S.C. Clement, Efficacy of exenatide therapy over 12 months in a "real world" setting (Abstract). Diabetes 56(supplement1) A512; 570-P. (2007)
10. A.B. King, G. Wolfe, S. Healy, Clinical observations of exenatide treatment. Diabetes Care 29, 1984 (2006)
11. R.J. Heine, L.F. Van Gaal, D. Johns, M.J. Mihm, M.H. Widel, R.G. Brodows, GWAA study group, Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann. Intern. Med. 143, 559-569 (2005)
12. L. Blonde, E.J. Klein, J. Han, B. Zhang, S.M. Mac, T.H. Poon, K.L. Taylor, M.E. Trautmann, D.D. Kim, D.M. Kendal, Interim analysis of the effects of exenatide treatment on A1c, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes. Metab. 8, 436-447 (2006)
13. M.A. Nauck, S. Duran, D. Kim, D. Johns, A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 50, 259-267 (2007)
14. M.C. Riddle, R.R. Henry, T.H. Poon, B. Zhang, S.M. Mac, J.H. Holcombe, D.D. Kim, D.G. Maggs, Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab. Res. Rev. 22(6), 483-491 (2006)
15. R.E. Ratner, D. Maggs, L.L. Nielsen, A.H. Stonehouse, T. Poon, B. Zhang, T.A. Bicsak, R.G. Brodows, D.D. Kim, Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 8(4), 419-428 (2006)